OTCPK:IPCIF (Canada)  
IntelliPharmaCeutics International Inc logo

IntelliPharmaCeutics International Inc

$ 0.08 0 (0%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 2.48M
Enterprise V:
$ 4.41M
Volume:
100.00
Avg Vol (2M):
4.18K
Also Trade In:
Volume:
100.00
Market Cap $:
2.48M
PE Ratio:
At Loss
Avg Vol (2-Month):
4.18K
Enterprise Value $:
4.41M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain. The company's lead product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.04
Equity-to-Asset -7.07
Debt-to-Equity -0.2
Debt-to-EBITDA -0.59
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -118.88
Distress
Grey
Safe
Beneish M-Score -10.93
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 41.73
9-Day RSI 41.32
14-Day RSI 43.27
6-1 Month Momentum % -20.74
12-1 Month Momentum % -17.83

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.05
Quick Ratio 0.05
Cash Ratio 0.01
Days Sales Outstanding 268.49

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.9

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -3707.13
Net Margin % -3876.95
ROA % -184.43
ROIC % -122.27
ROC (Joel Greenblatt) % -332.01

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 25
EV-to-EBIT -1.26
EV-to-EBITDA -1.34
EV-to-Revenue 45.22
EV-to-FCF -3.01
Earnings Yield (Greenblatt) % -79.37

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:IPCIF

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.102
EPS (TTM) ($) -0.13
Beta 1.42
Volatility % 37.72
14-Day RSI 43.27
14-Day ATR ($) 0.004219
20-Day SMA ($) 0.086749
12-1 Month Momentum % -17.83
52-Week Range ($) 0.077 - 0.2998
Shares Outstanding (Mil) 33.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

IntelliPharmaCeutics International Inc Filings

Document Form Filing Date
No Filing Data

IntelliPharmaCeutics International Inc Analysis

Share your research

Headlines

See More
No news.